Sponsored by
Just a quick update to show how YOUR donations are being used!
Musella Foundation Grant Award to Tocagen - Interim Progress Report
The Musella Foundation recently awarded Tocagen Inc. (http://www.tocagen.com) a grant to support the clinical investigation of Toca 511 & Toca FC in patients with recurrent Grade 3 glioma brain cancer (http://www.prweb.com/releases/2012/7/prweb9702371.htm). Since awarding this grant, we are pleased to report that Tocagen has enrolled three Grade 3 patients that have been supported, in part, by this grant. It is innovations like Toca 511 & Toca FC that we believe may make a difference in the lives of these patients.
Toca 511 & Toca FC is designed to kill cancer cells from within while leaving healthy cells unharmed. Tocagen is enrolling patients across the U.S. in two multicenter, open-label investigational clinical trials. These studies are evaluating patients with recurrent high-grade glioma, who have had prior surgery and chemoradiation. In one study, Toca 511 is delivered directly to the tumor under real-time MRI guidance while in the second protocol, Toca 511 is injected into the walls of the resection cavity immediately following removal of the tumor. More details can be found on http://www.virtualtrials.com by searching for Tocagen under the “Find a Treatment” tab.